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Mouse models for Huntington’s Disease (HD) and HD patients demonstrate motor and behavioral dysfunc-
tions, such as progressive loss of coordination and memory, and share similar transcriptional profiles and
striatal neuron atrophy. Clear differences between the mouse and human diseases include almost complete
striatal degeneration and rarity of intranuclear inclusions in HD, and the fact that mice expressing full-length
mutant huntingtin do not demonstrate a shortened life span characteritstic of HD. While no clinical interven-
tions tested in mouse models to date have delayed disease progression, the mouse models provide an
invaluable tool for both investigating the underlying pathogenic processes and developing new effective
therapies. Inherent differences between humans and mice must be considered in the search for efficacious
treatments for HD, but the striking similarities between human HD and mouse models support the view that
these models are a biologically relevant system to support the identification and testing of potential clinical
therapies.Introduction
Huntington’s disease (HD) is a progressive, fatal neurodegener-
ative disorder characterized bymotor, cognitive, behavioral, and
psychological dysfunction. The cause of HD is an expansion
within a trinucleotide poly(CAG) tract in exon 1 of the huntingtin
(HTT) gene (The Huntington’s Disease Collaborative Research
Group, 1993). Age of onset is roughly inversely correlated with
the length of the CAG tract, which causes disease when 39
or more CAG repeats are present (Nørremølle et al., 1993).
Affecting approximately 1 in 10,000 people worldwide (Myers
et al., 1993), themost obvious pathology is progressive neurode-
generation, particularly within the striatum (caudate and puta-
men). The massive loss of neurons in this region, normally
responsible (among many things) for facilitation of volitional
movement, is believed to lead to the characteristic motor
dysfunctions of HD, such as uncontrolled limb and trunk move-
ments, difficulty maintaining gaze, and general lack of balance
and coordination (Bates et al., 2002). Neuronal loss or dysfunc-
tion also leads to cognitive problems, behavioral abnormalities,
and psychological dysfunction, some of which are reported
before motor abnormalities are noticeable. Importantly, some
patients present with a more rigid, Parkinsonian form of the
disease, typical when age of onset is under 20 (so called juvenile
onset cases). These children generally have large repeats, up to
120 for a 3-year-old patient (Cannella et al., 2004). The distinctive
features of juvenile HD cause many investigators to think of it as
a discrete subform of HD that may involve distinctive patholog-
ical processes.
Expanded poly(CAG) HTT leads to production of huntingtin
protein with an equally expanded polyglutamine (polyQ) stretch
near the N terminus. Despite a lack of consensus on the function
of wild-type huntingtin (wtHTT), it is well established through
studies of human tissue, cellular models, and animal models
that mutant polyQ huntingtin (mHTT) exerts a gain of toxic func-tion through aberrant protein-protein interactions. Inclusions
containing mHTT, wtHTT, ubiquitin, and many cellular proteins
(Hoffner and Djian, 2002) are seen in patients and animal models.
These aggregates are not necessarily toxic, but they are
commonly observedwherevermHTT is expressed. That thesame
aggregatesandcellular toxicity observed in humansarealso seen
inmanymodels,withdrastically different timescales (fromdays in
tissue culture to decades in human HD), accentuates the impor-
tance of expression levels and protein context in cellular
pathology. This is particularly evident in thewide variety of pheno-
typic progression seen in themanymousemodels of HD,which is
the subject of this review.
A mutant HD gene is present in the body of an individual from
conception. The potential for beneficial therapeutic intervention
is therefore present throughout the life of an affected individual.
However, the physiological consequences of the presence of the
HD mutation differ as life progresses. A key issue in utilizing
a mouse model to test therapeutic intervention for HD is to
assess which stage of disease a model corresponds to at any
given point in time. Some strains display neuropathology from
birth and early mortality, while others progress so slowly
that visible phenotypes are not seen until the mice are very old,
and do not present with morbidity. The age of onset of a number
of frequently utilized behavioral and biological measures of
pathology for HD mouse models are summarized in Figure 1.
The first transgenic model of HD in mice was developed in
1996 (Mangiarini et al., 1996) by introducing a fragment of a juve-
nile HD patient’s HTT gene into the mouse genome. Although
these strains (R6/2 and R6/1) were initially designed to study
repeat expansion, these strains displayed motor and metabolic
symptoms, including tremors, lack of coordination (rotarod
balance difficulty), and excessive weight loss, leading to death
at a very early age (12–14 weeks in the R6/2 line). The rapid and
reproducible progression of HD-like symptomology in R6/2 miceNeuron 69, February 10, 2011 ª2011 Elsevier Inc. 423
Figure 1. Timeline of Behavioral and Neuropathological Symptoms in Selected HD Model Mice
Strains are categorized by color: red indicates N-terminal transgenic, blue indicates full-length transgenic, and green indicates knockin.
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tations of R6/2, the absence of a full-length mutant HTT protein
and the extremely rapid progression of disease led to the devel-
opment of quite a number of other animal models, each with their
own unique genetic and phenotypic characteristics summarized
in Table 1.
Mouse models of HD can be grouped into three categories,
based on the genetic basis of their creation. N-terminal trans-
genic animals are those carrying a small 50 portion of huntingtin,
either human or chimeric human/mouse, at random in their
genome. These animals tend to have the earliest onset of motor
symptoms and diminished life span (Carter et al., 1999; Hodges
et al., 2008; Mangiarini et al., 1996; Schilling et al., 1999, 2004),
thought to be because mHTT pathology is greatly enhanced by
(though maybe not dependent on [Gray et al., 2008]) its proteo-
lytic processing into N-terminal fragments (Graham et al., 2006;
Li et al., 2000); these mouse models are probably a shortcut to
this particularly toxic state.
Transgenic models expressing full-length mHTT also exist,
containing random insertions of the full-length human HTT
gene with an expanded CAG repeat in the form of either YAC
or BAC DNA (Gray et al., 2008; Hodgson et al., 1999; Seo
et al., 2008; Slow et al., 2003). One interesting observation of
the two most commonly used models in this category is the
unexpected age of onset difference (6 months in YAC128424 Neuron 69, February 10, 2011 ª2011 Elsevier Inc.mice and as early as 8weeks in BACHDmice) despite the shorter
repeat length of BACHD mice (97 versus 128).
Several strains in which a pathological-length CAG repeat is
introduced into the mouse huntingtin (Htt) gene have also been
created (so called knockin strains) (Heng et al., 2007; Kennedy
et al., 2003; Levine et al., 1999; Lin et al., 2001; Menalled et al.,
2003, 2002; Shelbourne et al., 1999; Wheeler et al., 1999,
2002). The longest repeat models (140 and 150 repeats) have
motor symptom onset within 6 months, but the shorter models
have little or no observable motor dysfunction for the first year
of life, and no decrease in life span has been reported in any
knockin models. This may properly model the late adult onset
of human HD but does not replicate the impaired quality of life
and inevitable mortality.
Asmanymodels have been brought into use, significant differ-
ences among the models have emerged. It is important to note,
however, that many cross-model studies underline significant
pathological and molecular similarities in the different genetic
models in spite of their inevitable differences (Bennett et al.,
2007; Bjo¨rkqvist et al., 2008; Gine´s et al., 2006; Jenkins et al.,
2005; Kuhn et al., 2007; Luthi-Carter et al., 2002; Menalled
et al., 2000; Southwell et al., 2009; Strand et al., 2007; Walker
et al., 2008; Woodman et al., 2007). In this review we have
focused on specific pathological aspects of HD to compare
and contrast models.
Table 1. Commonly Used Mouse Models of HD
Strain
Name
Transgenic
or Knockin Gene Characteristics Promoter
Repeat
Length
Motor
Symptom
Onset Lifespan
Background
Strain(s) References
R6/2 Transgenic
fragment
Exon 1 of human
HTT gene
1 kb of
Human HTT
150 6 weeks 10–13 wks C57BL/6xCBA Mangiarini et al., 1996;
Carter et al., 1999
R6/1 Transgenic
fragment
Exon 1 of human
HTT gene
1 kb of
Human HTT
116 18 weeks 32–40 wks C57BL/6xCBA
or C57BL/6
Mangiarini et al., 1996;
Hodges et al., 2008
N171-82Q Transgenic
fragment
First 171 AA of
human HTT (exons 1,
2, part of 3)
Prnp 82 3 months 16–22 wks C57BL/6xC3H/He Schilling et al., 1999;
Schilling et al., 2004
Tg100 Transgenic
fragment
First 3 kb of
human HTT cDNA
Rat NSE 100 3 months
(nonspecific)
Normal C57BL/6xSJL Laforet et al., 2001
HD94 Transgenic
fragment
Chimeric human/
mouse HTT exon 1
TetO + tTA 94 4–8 weeks
(clasping)
Normal C57BL/6xCBA Yamamoto et al., 2000
YAC72 Transgenic
full-length
Full length
human HTT gene
Human HTT 72 16 months Normal FVB/N Hodgson et al., 1999;
Seo et al., 2008
YAC128 Transgenic
full-length
Full length
human HTT gene
Human HTT 120 6 months Normal FVB/N Slow et al., 2003
BACHD Transgenic
full-length
Full length
human HTT gene
(floxed exon 1)
Human HTT 97 (mixed) 2 months Normal FVB/N Gray et al., 2008
HdhQ72,
Q80
Knockin Endogenous murine
Htt gene, expanded
CAG inserted
Mouse Htt 72,80 12 months Normal Mixed 129Sv,
C57BL/6
Shelbourne et al., 1999;
Kennedy et al., 2003
HdhQ111 Knockin Endogenous murine
Htt gene, chimeric
human/mouse exon 1
Mouse Htt 109 24 months
(gait)
Normal Mixed 129Sv,
CD1
Wheeler et al., 1999;
Wheeler et al., 2002
HdhQ94 Knockin Endogenous murine
Htt gene, chimeric
human/mouse exon 1
Mouse Htt 94 2 months
(rearing)
Normal Mixed 129Sv,
C57BL/6
Levine et al., 1999;
Menalled et al., 2002
HdhQ140 Knockin Endogenous murine
Htt gene, chimeric
human/mouse exon 1
Mouse Htt 140 4 months Normal Mixed 129Sv,
C57BL/6
Menalled et al., 2003;
Hickey et al., 2008
HdhQ150 Knockin Endogenous murine
Htt gene, expanded
CAG inserted
Mouse Htt 150 100 weeks Normal Mixed 129Ola,
C57BL/6
Lin et al., 2001;
Heng et al., 2007
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HD in patients is characterized by motor, cognitive, and behav-
ioral symptoms, and assays testing these broad categories are
used to measure progression of pathology in HD mice. Motor
phenotypes have been tested in a number of HD model mice,
including limb clasping upon tail suspension, basal activity level,
gait abnormalities, balance beam traversing time, swimming
speed, suspended horizontal beam turning, and latency to
remain on a fixed-speed or accelerating rotarod. The rotarod,
in particular, has proven to be a robust quantitative measure-
ment of balance and coordination deficits for which nearly every
HD model mouse has demonstrated a deficiency. N-terminal
transgenic mice consistently display an early onset of severe
motor symptoms. R6/2 mice swim poorly by 5 weeks of age
and show beam-walking and rotarod deficiencies by 6 weeks,
both of which progressively worsen with age (Carter et al.,
1999). R6/1 mice experience clear rotarod deficiency at 18
weeks (Hodges et al., 2008) with an earlier (13 week) onset of
failure to turn around on a suspended horizontal rod (van Dellenet al., 2000), and N171-82Q mice display a subtle but progres-
sive rotarod phenotype at 3 months (Schilling et al., 1999).
Full-length transgenic models display delayed motor symp-
toms compared to N-terminal transgenics; YAC72 mice do not
display a significant rotarod phenotype until 16 months (Seo
et al., 2008), while YAC128 mice decline starting at 6–7 months
(Slow et al., 2003; Van Raamsdonk et al., 2005c). BACHD trans-
genics do show a significant reduction in rotarod latency as early
as 4weeks of age, but they do not precipitously decline in perfor-
mance until 28 weeks; this is in contrast to R6/2 rotarod perfor-
mance, which rapidly declines once a difference is measured
(Menalled et al., 2009).
Knockin mice do not always display the characteristic motor
phenotype seen in transgenic models, despite some strains
carrying as many CAG repeats as R6/2 mice (150) and having
twice the gene dose as most transgenic strains (behavioral
experiments carried out in knockin mice typically use homozy-
gotes). This could reflect differences in chromosomal context,
transgene expression, the chimeric nature of knockinHtt inserts,Neuron 69, February 10, 2011 ª2011 Elsevier Inc. 425
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4 months at 30 rpm on a fixed-speed rotarod (Hickey et al.,
2008), but another group reported no accelerating rotarod
phenotype through 6 months (Dorner et al., 2007), while rotarod
deficits are not seen in HdhQ92, HdhQ111, and HdhQ150 mice
until about 2 years of age (Heng et al., 2007; Menalled et al.,
2009; Trueman et al., 2009).
Cognitive phenotypes can again be measured in many ways,
but tasks based on spatial learning and memory such as the
Morris water maze or T maze (swimming or elevated) have
been used to reveal deficits in initial task learning and relearning
upon parameter changes. Four- to five-week-old R6/2 mice
learn the Morris water maze as well as wild-types when the
platform is visible but display spatial memory deficits when the
platform is hidden, and cannot relearn upon platform movement
as well as wild-type mice. Two-choice swim testing revealed an
earlier deficit in task reversal (6.5 weeks) than for initial visual
learning of the task (10-11 weeks) (Lione et al., 1999). Initial visual
learning deficiency of the two-choice swim test was also found in
YAC128 mice (Van Raamsdonk et al., 2005c), but HdhQ150
knockins displayed no learning deficits on the Morris water
maze (Heng et al., 2007).
Cognitive tests are challenging to standardize as environ-
mental conditions and spatial cues are difficult to replicate
from lab to lab and can influence animals’ performance in behav-
ioral tests. Despite these challenges, these consistent observa-
tions from many different labs demonstrating a clear effect on
cognitive performance in HD model mice suggests that the
cognitive decline commonly observed in HD patients is well rep-
resented by HD model mice.
Neuropathology
Human neuropathology is characterized by a severe loss of stria-
tal volume (in particular the caudate nucleus). Medium spiny
neurons, but not interneurons, are lost, and reactive gliosis is
apparent (Sharp and Ross, 1996). Cortical degeneration is also
prominent in late stages. HTT inclusions in patients are only
found in a small fraction of cells (Gourfinkel-An et al., 1998),
though they are visible in almost all HD patient brains with a clin-
ical grade of at least 2 (Herndon et al., 2009). Within HD model
mice, the progressive neuropathology is unique for each strain,
but they share some commonalities.
N-terminal transgene strains display neuropathology at or
prior to symptom onset. In contrast to patients, neuron loss is
somewhat minimal, but R6/2 brains decrease in weight as
much as 20% with enlargement of the lateral ventricles (Mangi-
arini et al., 1996). They demonstrate neuronal intranuclear inclu-
sions (NIIs) as early as at birth (Stack et al., 2005), though NIIs
are typically reported in this strain around 3–4.5 weeks (Davies
et al., 1997; Meade et al., 2002; Morton et al., 2000), significantly
prior to onset of easily observed symptoms. Inclusions were
found in the cortex, striatum, cerebellum, spinal cord, and hippo-
campus, and progressively increase in prevalence and size
(Meade et al., 2002). Despite this, chimera studies suggest that
medium spiny neurons (MSNs) bearing large inclusions can
survive for almost a year (Reiner et al., 2007) when surrounded
by wild-type cells. R6/2 MSN dendritic diameters and spine
density also decrease with age (Klapstein et al., 2001).426 Neuron 69, February 10, 2011 ª2011 Elsevier Inc.R6/1 mice share most of the R6/2 pathology but at a later age.
NIIs appear by 9 weeks (Naver et al., 2003), and R6/1 mice also
show minimal gliosis (Yu et al., 2003) and similar dendritic spine
atrophy by 8 months (Spires et al., 2004). Apoptotic and necrotic
cells are rarely seen in the striatum of R6/2 and R6/1 mice,
despite significant atrophy and ventricular enlargement; instead,
electron micrographs contain so-called dark neurons, displaying
condensation of the cytoplasm and nucleus without the chro-
matin fragmentation and nuclear blebbing characteristic of
apoptosis (Yu et al., 2003). In contrast, 3-month-old N171-82Q
mice do demonstrate cortical and striatal apoptotic neurons,
with reactive gliosis by 4 months. Note that in old (22–30 week)
R6/2 chimeras, gliosis is apparent in regions densely populated
in transgenic neurons (Reiner et al., 2007), and particularly old
R6/2 animals (17 weeks) show astrocytes with processes envel-
oping degenerating neurons (Turmaine et al., 2000). Therefore,
the signals necessary to develop gliosis in R6/2 mice may be
present, but the mice may die before glial recruitment and
activation. N171-82Q mice also presented with striatal degener-
ation and ventricular enlargement by 17 weeks (Gardian et al.,
2005) and NIIs in many brain regions (cortex, hippocampus,
cerebellum, and striatum among others) by late endstage of
6.5 months.
NIIs are not seen until far after symptom onset in full-length
transgenic HD lines. YAC128 mice display behavioral symptoms
at 12 months, and striatal neuron loss of 15% is seen by this
time (Slow et al., 2003) along with increased intranuclear HTT
staining of certain brain structures (Van Raamsdonk et al.,
2005a). However, NIIs did not show up until 18 months of age
and only populated 30% of striatal neurons and 5% of
cortical neurons. NIIs were absent in the YAC128 hippocampus,
a site of NII staining in endstage R6/20s (Morton et al., 2000). In
the other distinct full-length transgenic strain, BACHD mice
also display atrophy of the cortex and striatum by as much as
30% at 12 months (Gray et al., 2008), with 14% of striatal
neurons with the aforementioned dark morphology. Interestingly
and as opposed to R6mice, inclusions (over 90%) were extranu-
clear and were more common in the cortex than striatum,
a feature reminiscent of adult onset HD.
R6/2 chimaeras suggest that inclusions themselves may be
neither toxic nor markers of cells about to die, and a strain arising
with a spontaneous mutation in the YAC128 transgene [termed
Shortstop (Ss) for its early termination] provides further evidence
to this end (Slow et al., 2005). The mutation truncated the trans-
gene after exon 2, providing a product with 128 glutamines and
an expected and observed protein size similar to that encoded
by the R6/2 transgene. NIIs are particularly common (90% of
striatal, cortical, and hippocampal cells) and appear earlier in
Ss mice versus YAC128s; however, Ss mice had no obvious
phenotype at all ages examined. Why this strain is free from
the early onset behavioral symptoms one would expect in what
is essentially an N-terminal transgene HD model is still under
investigation.
Knockin mouse neuropathology, as with their symptoms,
usually occurs very late in life and is minor in comparison to
transgenic strains. HdhQ72-80 mice demonstrate loss of brain
weight by 16 months (Shelbourne et al., 1999), while NIIs are
primarily seen in striatal MSNs. Knockins with 94 repeats
Neuron
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while HdhQ111 mice show NII appearance at an earlier age
(10 months), and mHtt nuclear accumulation is evident at
a very early (6 weeks) age (Wheeler et al., 2000). HdhQ150
knockins lose as much as 40% of striatal volume and neurons
by 23 months, but significant gliosis and NIIs appear by 10–14
months (Heng et al., 2007; Lin et al., 2001; Tallaksen-Greene
et al., 2005; Yu et al., 2003). Degenerating neurons are not
apoptotic in this strain, though occasional dark neurons are
encountered. Knockin mice with 140 CAG repeats display rela-
tively early onset striatal NIIs and neuropil aggregates (4 months)
becoming progressively stronger in other brain regions aswell by
6 months (Menalled et al., 2003). These data do not imply that
knockin brains only present with abnormality in old age, as
HdhQ111 embryos demonstrate impaired neurogenesis as early
as embryonic day 13.5 (Molero et al., 2009).
Protein context clearly influences neuropathology and symp-
toms in HD, as other polyglutamine disorders such as SBMA,
DRPLA, and the various spinocerebellar ataxias (reviewed in
Yamada et al., 2008) produce distinct vulnerable neuronal pop-
ulations and motor symptoms. Posttranslational modifications
influence progression, as ablation of caspase-6 cleavage sites
within the YAC transgene yields a mouse that demonstrates no
behavioral symptoms or striatal atrophy along with a delay in
mHTT translocation to the nucleus (Graham et al., 2006). Also,
while only 17 residues lie N-terminal to the polyQ repeat in
human HTT, these play a role in neuropathology; phosphomi-
metic mutations of serines 13 and 16 prevent aggregation and
symptom onset in parallel BACHD lines (Gu et al., 2009).
While inclusions are a historic histological hallmark of HD,
evidence continues to mount that their presence does not corre-
late with toxicity, as seen in chimaeric R6/2 or in Ss mice. The
theory that inclusions represent a sequestration site for mHTT,
while smaller oligomers mediate toxicity, is consistent with
neuropathological data in mice but is hard to prove with causa-
tive data. It represents an intriguing therapeutic option though,
that perhaps altering aggregation kinetics by accelerating mac-
roaggregation or reducing oligomerization would slow toxicity.
Cell Autonomous versus Nonautonomous Pathology
Neurodegeneration in HD affects multiple brain regions, but
striatal degeneration has been the focus of much of the research
field for two reasons: the massive loss of neurons suggests
a particular vulnerability of striatal MSNs and, more specifically,
the characteristic motor phenotype is classically attributed to the
early loss of one of two nearly identical arms of the corticostriatal
loop, the indirect (striatopalladial) pathway. Nevertheless, recent
research suggests that multiple cell types in the brain contribute
to pathology. Driving an expanded poly(CAG) HTT fragment in
glial (GFAP+) cells also induces many features in common with
other mouse models of HD (clasping, failure to keep on weight,
rotarod phenotype, and premature death), albeit at a later time
than is common for models expressing N-terminal transgenes
in neurons (Bradford et al., 2009). This is interesting when one
considers the stark phenotype of the N171-82Q mice, whose
N-terminal transgene is driven primarily in neurons by the prion
promoter (Schilling et al., 1999). However, a conditional model
of HD suggests that expression of mutant HTT in multiple celltypes is required for motor symptoms. A lox-STOP-lox poly
(CAG) HTT exon 1 strain mated to Nestin-Cre mice (pan-
neuronal expression) induced a behavioral phenotype at
6 months of age, but mating it to Emx1-Cre (cortical pyramidal
cell expression) (Gu et al., 2005) or Dlx5/6-Cre mice (striatal
MSN expression) produced EM48+ aggregates in the expected
brain regions but no observed motor phenotype; the animal’s
short life spanmay limit phenotypic progression in thesemodels.
Taken as a whole, we can see that mutant HTT can cause neuro-
pathology (aggregate formation at the least) in nearly every
neuronal or glial cell in which it is expressed, and while MSN
expression plays a large role, cells other than MSNs can
contribute tomanifest disease in mice. This has particular impor-
tance from a therapeutic perspective, as it suggests that drugs
that by default cannot affect neurons (e.g., the target enzyme
is not expressed in neurons) should not a priori be set aside.
Excitotoxicity
An important and unanswered question in the HD field is what
mediates the specific vulnerability of striatal MSNs, leaving stria-
tal interneurons, glia, and other brain regions less damaged. The
observation that kainic acid (KA), a structural analog of the excit-
atory neurotransmitter glutamate, produced striatal degenera-
tion reminiscent of HD (Coyle and Schwarcz, 1976) while sparing
dopaminergic projections suggested overactivation of postsyn-
aptic glutamate receptors damages MSNs. Another glutamate
analog, quinolinic acid (QA), was later tested (Beal et al., 1991,
1986) and produced a similar lesion as KA, but spared cholin-
ergic interneurons, making it a particularly similar animal model
for HD. These experiments brought forward the excitotoxicity
hypothesis, that MSNs in HD are sensitive to overactivation of
glutamate receptors (specifically NMDA receptors) resulting in
excessive Ca2+ and other ionic influx and selective death.
Excitotoxicity was later assayed in genetic HDmouse models.
R6/1 and R6/2 mice injected presymptomatically (18 weeks and
6 weeks, respectively) displayed marked resistance to excito-
toxic lesions compared to wild-type littermates (Hansson et al.,
1999); this resistance was progressive with age. N171-82Q
mice displayed resistance to intrastriatal QA administered at
15 weeks (Jarabek et al., 2004), and asymptomatic shortstop
mice are also QA resistant (Slow et al., 2005), but this phenotype
is not ubiquitous among the N-terminal transgene strains.
TgHD100 mice, which express the N-terminal 1/3 of HTT with
100CAGs at about 30%endogenous levels, display no alteration
of QA lesion size (Peterse´n et al., 2002). Older R6mice have five-
fold higher basal levels of Ca2+, suggesting that resistance might
be the result of compensatory mechanisms (Hansson et al.,
2001). Modest protection from mHTT is observed upon decorti-
cation or administration of glutamate release inhibitors, gluta-
mate transporter upregulators, mGluR5 antagonists, and
mGluR2/3 agonists (Miller et al., 2008; Schiefer et al., 2002;
Schiefer et al., 2004; Stack et al., 2007). YAC mice display early
QA sensitivity but a progressive loss of sensitivity, becoming
resistance toQA in 10month YAC128mice (Graham et al., 2009).
In at least four HD mouse models, there is consistent resis-
tance to excitotoxic stress, either presymptomatic (R6/1, R6/2,
and N171-82Q) or after symptom onset (YAC128). The nature
of the resistance phenotype is still under investigation but mayNeuron 69, February 10, 2011 ª2011 Elsevier Inc. 427
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son et al., 2001) combined with decreases in dendritic spine
density and length (Klapstein et al., 2001; Spires et al., 2004).
All told, we see that MSNs are particularly vulnerable to exces-
sive Ca2+ influx, but that, over time, the neurons compensate
for this to a certain extent. However, even the loss of normal glu-
tamatergic afferents increases neuronal survival, suggesting that
despite tolerance to acute excitotoxic insult, corticostriatal
glutamate signaling still contributes to neuropathology in HD.
Mitochondria and Energy Imbalance
Neurons, requiring very high metabolic ATP synthesis for main-
tenance of membrane polarization, are sensitive to perturbations
of mitochondrial activity. Rodent MSNs seem particularly sensi-
tive. Chronic systemic administration of a low dose of succinate
dehydrogenase inhibitor 3-nitropropionate (3-NP) in rats induced
a massive loss of MSNs but relative sparing of interneurons and
dopaminergic afferents (Beal et al., 1993). The toxicity of 3-NP in
rats is significantly ameliorated by dietary creatine supplements
(Matthews et al., 1998), a compound that also improved survival,
rotarod latency, weight, and neuronal atrophy in R6/2 (Ferrante
et al., 2000) and N171-82Q mice (Andreassen et al., 2001).
R6/2, HdhQ92, and HdhQ111 striatal mitochondria become
progressively desensitized to Ca2+ depolarization over time by
3, 12, and 3 months of age, respectively (Brustovetsky et al.,
2005). Total forebrain mitochondria also show increase in
Ca2+-buffering capacity in 12 week R6/2 and 12 month
YAC128 mice prior to permeabilization, though no difference
was seen in 16 week HdhQ150 mice (Oliveira et al., 2007) at an
age when subtle gait abnormalities are visible (Lin et al., 2001).
These observationsmay be indicative of progressive compensa-
tion to heightened baseline Ca2+ levels in agedHDmouse striatal
neurons, perhaps also mediating QA resistance. Mitochondrial
biogenesis deficiencies may be a contributing factor, as PGC-
1a, a positive regulator of mitochondrial biogenesis, is reduced
in both human HD samples and 12 month HdhQ140 striatal
MSNs (but is elevated in interneurons) (Cui et al., 2006). Distur-
bances of mitochondria in HD are perhaps not surprising, given
neuronal ATP requirements, and the data demonstrate that
mHTT can perturb mitochondrial calcium sensitivity.
The hypersensitivity of MSNs to a mitochondrial poison,
combined with the mouse mitochondrial perturbations and
a general metabolic deficit in HD patients, strongly suggest
that both CNS and peripheral symptoms of HD are influenced
by altered mitochondrial function.
Electrophysiology
Many motor and behavioral symptoms in HD arise from the
massive loss of MSNs, and the motor symptoms that acute
3-NP and QA toxicity produce are reminiscent of advanced
HD. However, many mouse models of HD demonstrate almost
no neuronal death. That neurons can be intact but still clearly
malfunctioning, combined with the cognitive and memory defi-
cits seen in most patients, suggests that synaptic abnormalities
may be significant in HD pathology.
Disturbances in long-term potentiation (LTP) and long-term
depression (LTD) are presented as evidence of a synaptic plas-
ticity dysfunction, and such abnormal responses to LTP and428 Neuron 69, February 10, 2011 ª2011 Elsevier Inc.LTD are seen in almost all mouse HD models. Asymptomatic
heterozygous HdhQ72-80 mice displayed impaired hippo-
campal LTP between 8 and 14 months of age (Usdin et al.,
1999), as did YAC46 and YAC72 by 6 months (Hodgson
et al., 1999); R6/2 averaged from 5 weeks to endstage (Murphy
et al., 2000). HdhQ92 and HdhQ111 displayed impairment at 2
months old and 4–6 months old, respectively, and HdhQ140
mice at only 8 weeks old (Simmons et al., 2009). LTD was also
abnormal in R6/2 s (Murphy et al., 2000) and R6/1 s (Cummings
et al., 2007; Cummings et al., 2006). LTP or LTD deficits have not
been reported in BACHD mice, but reduction in high-amplitude
mEPSCs of MSNs at 6 months (Gray et al., 2008), as well as
cortical synaptic alterations at the same age (Spampanato
et al., 2008) demonstrate somecorticostriatal circuitry impairment
in this strain as well. As impaired performance at cognitive tasks
such as the Morris water maze or T maze is seen in R6/2 s (Lione
et al., 1999) and YAC128 (Van Raamsdonk et al., 2005c) animals,
aswell as somatosensory associativememoryproblems inR6/1 s
(Cybulska-Klosowicz et al., 2004), the LTP and LTD impairments
probably represent behaviorally relevant plasticity deficits.
Because these phenotypes exist in mice that recapitulate many
HD patholgic features but without massive neuronal loss, these
studies suggest that in spite of the massive loss of neurons in
HD, it is likely that defects within existing neuronal circuits
contribute to early behavioral symptoms.
CAG Expansion
The CAG repeats within human HD and mouse HD models are
prone to mutation, both in the germline and in somatic tissue.
Germline expansions are more common in males (Wheeler
et al., 2007), correlating with baseline mutant repeat length,
and are thought to occur during mitosis, based on the very
high percentage of sperm found with mutated alleles (averaging
over 80%) (Leeflang et al., 1999).
R6/2 mice are notoriously prone to intergenerational CAG
repeat expansion (Morton et al., 2009). This has prompted
many labs studying this strain to adopt a selective breeding
strategy using only breeders with the desired number of repeats.
R6/1 mice are almost as prone to expansions as R6/2 s (Mangi-
arini et al., 1997), but contractions are also seen, notably an R6/1
substrain with 89 CAG repeats that demonstrates a later onset of
neuropathology andmotor symptoms than standard R6/1 s (Vat-
savayai et al., 2007). Interestingly, in spite of the fact that CAG
repeat length is the strongest correlate for age of onset in HD,
R6/2 substrains carrying anywhere from 150 to over 400 repeats
have demonstrated that in this transgene and background,
higher CAG lengths strongly correlate with a later age of onset
(Morton et al., 2009), perhaps because of changes in mHTT
subcellular localization. Knockin mice also demonstrate inter-
generational CAG repeat-length instability, with more mutations
seen in mice with higher repeat lengths (HdhQ92, HdhQ111) and
higher rates in males (Ishiguro et al., 2001; Shelbourne et al.,
1999; Wheeler et al., 1999). We are not aware of germline insta-
bility in YAC HD model mice, but BACHD mice do not expand
because of the alternating CAA-CAG repeats of the transgene
(Gray et al., 2008).
Somatic poly(CAG) instability is also observed in most HD
model mice; that BACHD mice display symptoms despite the
Neuron
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sions are not required for neuropathology. However, knockins
(HdhQ111) lacking DNA mismatch repair enzyme Msh2 had de-
layed intranuclear mHtt accumulation with absence of somatic
CAG repeat expansion (Wheeler et al., 2003). Msh2 knockout
R6/1 mice also lacked somatic expansion (Manley et al., 1999).
HdhQ72-80 knockins also display prominent striatal, cortical,
and cerebellar expansions, and HdhQ150 animals show somatic
expansions as early as at 4 months of age. (Kennedy et al., 2003;
Kennedy and Shelbourne, 2000).
The phenotype of BACHD mice clearly demonstrates that
somatic CAG expansion is unlikely to be a major driving force
in early disease onset. A possible propensity to cancer that could
arise from reducing the activity of mismatch repair proteins also
demands caution in exploring this specific pathway for HD
therapy. Nevertheless, the mouse Msh2 ablation studies and
correlation of expansions to patient samples demonstrate that
somatic expansion may contribute to HD.
Transcriptional Dysregulation
Abnormal interactions between mHTT and transcription factors
may play a prominent role in neuropathology, and, as they are
expected to be quite pleiotropic, it suggests both an intriguing
explanation for the wide-ranging systems disrupted in HD
neurons as well as a promising target for therapy. The reduction
of neurotransmitter receptors in the HD striatum (Glass et al.,
2000; Pavese et al., 2003; Weeks et al., 1996) is one of the
earliest observed symptoms, and mHTT is known to interact
with or sequester numerous transcription factors (Boutell et al.,
1999; Dunah et al., 2002; Huang et al., 1998; Nucifora et al.,
2001; Steffan et al., 2000). The advent of more advanced
transcriptional profiling in the last 10 years along with a bevy of
mouse models of HD have provided ample opportunity for
assaying this dysregulation and attempting therapies.
Microarray transcriptional profiles were compiled for R6/2
mice both before (6 weeks) and after (12 weeks) onset of overt
motor symptoms. Approximately 1.5% of transcripts displayed
altered levels at each age, with a majority (75%) displaying
decreased expression (Luthi-Carter et al., 2000). Many of these
transcriptional changes were verified in N171-82Q mice though
they were not shared by YAC72 mice (Chan et al., 2002). Further
analysis from this group demonstrated that 12-week-old R6/2,
16-week-old N171-82Q, and 12-month-old animals modeling
DRPLA (a disorder resulting from polyglutamine expansion in
the Atrophin-1 gene) all show significant overlap of cerebellar
profiles (Luthi-Carter et al., 2002). That cerebellar tissue and
also laser-capture microdissected interneurons (Zucker et al.,
2005) of R6/2 mice demonstrate transcriptional dysregulation
suggests that this phenomenon is not unique to the cells most
vulnerable to degeneration, nor are inclusion-bearing cells
more prone to transcriptionally altered neurotransmitter receptor
levels (Sadri-Vakili et al., 2006). What has been particularly
striking is the significant similarities in transcriptional profiles of
most genetic HD mouse models tested, both among each other
and with human HD. Simultaneous profiling of R6/1, R6/2,
HdhQ150, HdhQ92, and YAC128 mice demonstrated that every
model correlated significantly with every other model and with
humanHD,with the caveat that the strains had to be aged appro-priately (Kuhn et al., 2007). Other studies have reached similar
conclusions (Hodges et al., 2008; Strand et al., 2007).
Given that the global transcriptional changes are more
commonly downregulations than upregulations in HD model
mice (Luthi-Carter et al., 2000) and that there are altered
chromatin dynamics associated with repressed transcription
(increased methylation and decreased acetylation) (Stack
et al., 2007), it has been investigated whether general modifica-
tions to histone dynamics in the form of histone deacetylase
(HDAC) modulation could be therapeutic. Suberoylanilide hy-
droxamic acid (SAHA) and sodium butyrate, two HDAC inhibi-
tors, both caused a delay in motor symptom onset in R6/2
animals, though SAHA was toxic. (Ferrante et al., 2003; Hockly
et al., 2003). HDAC inhibitors 4b and valproate alleviated loco-
motor deficits in R6/2 and N171-82Qmice, respectively (Thomas
et al., 2008; Za´dori et al., 2009). N171-82Q mice demonstrated
marked improvement in life span, striatal atrophy, and histone
methylation:acetylation ratio upon administration of HDAC inhib-
itor phenylbutyrate after symptom onset, an important result for
a disease in which not every carrier chooses to know their gene
status and may only initiate treatment after overt symptoms are
detected (Gardian et al., 2005). In order to limit the off-target
effects of a general HDAC inhibitor, drugs with tighter specificity
are needed aswell asmore focused targets. Recently, R6/2mice
have been bred to strains carrying either homozygous (if not
lethal) or heterozygous deletions in HDACs to parse out
which HDACs are the best modifiers of pathology. So far
HDAC7 has been discounted as a potential modifier (Benn
et al., 2009), but HDAC4 does show some promise (G. Bates,
personal communication).
The similarity in transcriptional profiles between many aged
HD model mice and patient samples suggests a fundamental
consequence of mHTT on basal levels of transcription either by
direct interaction with transcription factors, attempts at compen-
satory changes, or both. That this phenotype is directly quantifi-
able in mice and correlates so strongly with patient samples
supports its utility as a biological measure for pathology.
From Preclinical to Clinical Treatment of HD
As we have discussed above, mouse models give insight into
many aspects of pathology observed in HD patients. That said,
the central question in front of us is how can mouse models
best be used to develop therapeutic intervention for HD.
Candidate-based approaches and success in mouse models
have resulted in many drug trials progressing from preclinical
mouse work to patients. The authors direct the readers to three
excellent reviews: Li et al. (2005) and Gil and Rego (2009)
enumerate the trials conducted in the R6 lines, and Mestre
et al. (2009) provide a detailed summary and discussion of pub-
lished HD clinical trials. Of those treatments tested in rodents,
many have made it to clinical trials; nine trials passing the Mestre
et al. (2009) criteria (randomized, placebo-controlled, symptom-
atic therapy with at least10 participants), plus the combination
remacemide/coenzyme Q10 trials, are listed in Table 2. The
majority of these selected clinical trials were aimed at safety
and tolerability, rather than efficacy, so it comes as little surprise
that no improvement in clinical outcome was seen for most. To
date, only tetrabenazine (TBZ) has demonstrated a reductionNeuron 69, February 10, 2011 ª2011 Elsevier Inc. 429
Table 2. Selection of Drugs Tested in Both HD Model Mice and in Clinical Trials with HD Patients
Drug Animal Model Animal Dosage Animal Duration Animal Effect Patient Dosage Patient Duration Patient Effect References
Cannabidiol 3-NP Rat 5 mg/kg daily From 12 weeks
for 5 days
a 10 mg/kg daily 6 weeks drug,
15 weeks obs.
n.s. Sagredo et al., 2007;
Consroe et al., 1991
Creatine R6/2 2% in chow
ad lib
From 21 days 18% improved
survival
8 g daily 16 weeks drug,
24 weeks obs.
n.s. Ferrante et al., 2000;
Hersch et al., 2006
Ethyl-EPA YAC128 1% in chow
ad lib
From 7 months 44% improved
rotarod
2 g daily 6 or 12 months
drug
n.s. Van Raamsdonk et al., 2005b;
Huntington Study Group
TREND-HD Investigators, 2008
Fluoxetine R6/1 20 mg/kg daily 10 to 20 weeks b 20 mg daily 4 months drug n.s. Grote et al., 2005;
Como et al., 1997
L-carnitine N171-82Q 250 mg/kg,
5x/week
From 6 weeks 15% improved
survival
45 mg/kg daily 1 week drug,
4 weeks obs.
n.s. Vamos et al., 2010;
Goetz et al., 1990
Minocycline R6/2 5 mg/kg daily From 6 weeks 13% improved
survival
200 mg daily 8 weeks drug n.s. Chen et al., 2000;
The Huntington Study Group 2004
Remacemide R6/2 0.007% in
chow ad lib
From 21 days 16% improved
survival
200 or 600 mg
daily
6 weeks drug n.s. Ferrante et al., 2002;
Kieburtz et al., 1996
Remacemide + CoQ10 R6/2 0.007% Rem,
0.2% CoQ10
in chow ad lib
From 21 days 32% improved
survival
600 mg each
daily
30 months drug n.s. Ferrante et al., 2002;
The Huntington Study Group, 2001
Riluzole R6/2 10 mg/kg daily From 21 days 10% improved
survival
200 mg daily 8 weeks drug n.s. Schiefer et al., 2002;
The Huntington Study Group, 2003
Tetrabenazine YAC128 5 mg/kg,
33/week
From 2 months 60% improved
rotarod
Up to 100 mg
daily
12 weeks drug 3.5 UHDRS units
improvement
Wang et al., 2010;
The Huntington Study Group 2006
aNo behavior tested; reduced striatal lesion size and some transcript reduction.
b n.s. on rotarod; protected against degeneration in dentate gyrus.
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Reviewof motor symptoms in both mice and patients (Frank, 2009; Hun-
tington Study Group, 2006; Tang et al., 2007; Wang et al., 2010),
and though the mouse studies showed a reduction in striatal
atrophy and motor symptoms, reduced neurodegeneration has
not been documented in human patients on TBZ.
A current challenge to therapeutic development in HD is the
identification of validated targets for HD therapy. Currently, there
is only one such target: huntingtin itself. Reduction in levels of
expression of HTT should be beneficial to HD patients if they
can be achieved. Mouse models strongly support this conten-
tion. Early work in conditional, reversible models of HD (Yama-
moto et al., 2000) demonstrated that silencing of the mutant
locus, even relatively late in pathology, results in not only halting
of disease progression but reversal of some pathologic
sequelae. More recently, two studies have shown that reduction
of mutant HTT levels in the brain of model mice, either by
reducing translational output of HTT via viral siRNA delivery
(Boudreau et al., 2009) or increasing protein clearance of HTT
by intrabody (intracellular antibody) expression (Southwell
et al., 2009), has a beneficial effect on behavior and neuropa-
thology in HD model mice. The demonstration of a therapeutic
benefit of these approaches in mouse models suggests that
these approaches could benefit patients as well. Perhaps
equally importantly, these studies give confidence that if new
validated targets are identified, mouse models will be valuable
in assessing how effective therapeutic intervention against these
targets might be.
However, refinements in the measurements of pathology are
needed to make the most out of mouse model studies. In the
last few years, clinical studies (volumetric MRI and functional)
have begun to provide useful measures to characterize HD
progression prior to the point in disease formally designated by
functional decline as onset. The modeling of this period (pre-
manifest HD) requires the development and validation of a set
of measures in the mouse that clearly correspond appropriately
to the progression of HD during this period in the human; for
example, imaging modalities such as MRI are being minaturized
for use in HDmodel mice (Sawiak et al., 2009; Zhang et al., 2010)
and show promise. We don’t yet have this correspondence well
established in the mouse for several reasons. First, and perhaps
foremost, many of the findings on premanifest HD are quite
recent. Second, assay strategies, particularly at the biological
level, may require deeper insight into the mechanisms of molec-
ular pathology in premanifest HD, including more powerful
transcriptional and translational profiling; for example, modern
transcriptional profiling by RNaseq will provide additional insight
as it allows linearity over a greater range of transcript levels than
arrays provide.
The mouse models of HD demonstrate a clear pathology, and
while some of the phenotypes (rotarod latency for example) have
limited direct relation to measurable patient symptoms, many
others (transcriptional profile changes) bear striking resem-
blance to patients. What the field now has is a collection of
mousemodels suited to study one ormore of the different stages
of human disease, a collection of measurable phenomena in
these mice (many of which are directly relatable to patient symp-
toms), and demonstration that targeting the protein at the root of
the pathology will effectively reduce or delay the symptoms.Continued studies of the mice give us a tremendous opportunity
to use a mammalian nervous system under similar stresses to
HDpatients, identify therapeutic candidates relevant to a specific
disease stage, and test therapies with the knowledge that it is
possible to at least partially rescue the cells from the toxic insult
of mHTT. It is hopefully only a matter of time before such studies
yield one or more therapeutics that effectively reduce neuropa-
thology in patients.REFERENCES
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